News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Deschatelets Pascal
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/10/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $40.38, valued at
$484.6k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
10/10/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/09/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $23.66, valued at
$283.9k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/11/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $84.55, valued at
$1M
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/09/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $91.35, valued at
$1.1M
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/09/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $92.39, valued at
$1.1M
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
05/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/10/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $63.79, valued at
$765.5k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
02/22/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Granted 9,886 shares
@ $0 Paid exercise price by delivering 1,195 shares
@ $58.5, valued at
$69.9k
Granted 14,023 options to buy
@ $35.46, valued at
$497.3k
|
|
02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/30/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Paid exercise price by delivering 832 shares
@ $52.77, valued at
$43.9k
|
|
01/24/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Paid exercise price by delivering 2,326 shares
@ $52.05, valued at
$121.1k
|
|
01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/10/2023 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $46.08, valued at
$553k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
12/30/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Exercised 7,000 options to buy
@ $3.67, valued at
$25.7k
|
|
12/12/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $47.5, valued at
$570k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
10/11/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $57.5, valued at
$690k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
09/12/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $63.98, valued at
$767.8k
Exercised 18,500 options to buy
@ $2.67, valued at
$49.4k
|
|
07/12/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 12,000 shares
@ $47.95, valued at
$575.4k
Exercised 12,000 options to buy
@ $2.67, valued at
$32k
Exercised 6,500 options to buy
@ $2.67, valued at
$17.4k
|
|
06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/02/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Disposed of 1,875 shares
@ $0 Sold 4,000 shares
@ $44.43, valued at
$177.7k
Disposed of 11,250 options to buy
@ $44.9, valued at
$505.1k
Exercised 4,000 options to buy
@ $2.67, valued at
$10.7k
|
|
02/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Paid exercise price by delivering 931 shares
@ $38.59, valued at
$35.9k
|
|
01/25/2022 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Granted 26,051 shares
@ $0 Granted 36,951 options to buy
@ $35.46, valued at
$1.3M
|
|
06/25/2021 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 6,250 shares
@ $65.61, valued at
$410.1k
Exercised 6,250 options to buy
@ $2.67, valued at
$16.7k
|
|
05/25/2021 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Exercised 6,250 options to buy
@ $2.67, valued at
$16.7k
Sold 6,250 shares
@ $47.4, valued at
$296.3k
|
|
04/29/2021 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Exercised 4,500 options to buy
@ $2.67, valued at
$12k
|
|
04/26/2021 |
4
| Deschatelets Pascal (Chief Scientific Officer) has filed a Form 4 on Apellis Pharmaceuticals, Inc.
Txns:
| Sold 6,250 shares
@ $46.13, valued at
$288.3k
Exercised 6,250 options to buy
@ $2.67, valued at
$16.7k
|
|
03/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|